Clinical Trial Update: Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing neoadjuvant aromatase inhibitor with ovarian suppression versus chemotherapy in premenopausal breast cancer; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• aromatase inhibitor with ovarian suppression

Snippet

Sponsor: Ruijin Hospital | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED